Nuvalent, Inc. is developing cancer therapies meant to overcome the limitations of existing therapies for clinically proven kinase targets. Its lead product candidate, NVL-520, is a brain-penetrant ROS1-selective inhibitor. Nuvalent was incorporated in 2017 and is headquartered in Cambridge, MA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$47.20 | A | |
$8.30 | A | |
$65.30 | A |